Pelvic Lymph Node Dissection in Prostate Cancer: Evidence and Implications.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40199676.
- Also identified by DOI 10.1016/j.eururo.2025.03.004.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The role of extended pelvic lymph-node dissection (ePLND) in prostate cancer has been revisited in light of evidence from studies on staging via prostate-specific membrane antigen positron emission tomography/computed tomography. It is difficult to predict which individuals might benefit from ePLND. Patients should be counselled about this uncertainty and the risks of ePLND-associated morbidity as part of the shared decision-making process.
Medical subject headings
- Lymph Node Excision
- Prostatic Neoplasms